Clinical Trial Update: Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial results update for durvalumab after radiation therapy in patients with stage 3 unresectable non-small cell lung cancer who are ineligible for chem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-09-25